Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

HopeMed of China In-Licenses Hair Loss/Endometriosis Treatment from Bayer

publication date: Apr 8, 2019

Hope Medicine, a China startup, acquired a global license from Bayer AG to develop and commercialize a mAb targeting the PRL receptor as a treatment for male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. HopeMed was spun out of the lab of Professor Rui-Ping Xiao at the Institute of Molecular Medicine at Peking University. Bayer and IMM collaborated to discover the candidate. HopeMed concurrently completed a Series A funding from Trustbridge Partners and Qi Rui You Kang, a China PE firm. More details....

Stock Symbol: (F: BAYN)

Share this with colleagues:

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020